RESUMEN
This study was aimed to preliminary explore the anticancer activity, immunomodulatory effects and antimi-crobial activity of Calcitum ashing agent. Serum pharmacological method was used to prepare the serum containing Calcitum ashing agent. MTT method was used to observe the cell proliferation rate of S180 ascites tumor cells and human esophageal cancer cells cultured with the serum containing Calcitum ashing agent in vitro. In addition, this method was also used to observe the mouse spleen lymphocyte transformation rate. The Oxford Cup method was used to determine the antibacterial activity on Calcitum ashing agent in vitro. The results showed that serum containing Calcitum ashing agent inhibited the cell proliferation rate of S180 and esophageal cancer cells. Meanwhile, it had a synergistic effect with 5-fluorouracil (5-FU) on the inhibition of human esophageal cancer cells. The serum contain-ing Calcitum ashing agent induced the reduction in the mice spleen lymphocytes transformation rate. But it inhibited the reduction in the spleen lymphocytes transformation rate induced by 5-FU. The decoction with the concentration higher than 0.25 g·mL-1 had significantly inhibited the proliferation of bacteria. It was concluded that Calcitum ash-ing agent can inhibit the cell proliferation of S180 ascites tumor cells and human esophageal cancer cell in vitro. It can significantly reverse the reduction in the mice spleen lymphocytes transformation rate induced by immunode-pressant. However, the antibacterial activity still requires further study.
RESUMEN
Aim To investigate the effect of polysac-charide of Cistanche deserticola ( CDPS) on the impro-ving ability of synaptic plasticity in memory acquisition impairment model mice induced by scopolamine. Methods The KM mice were randomly divided into six groups:scopolamine group, control group, CDPS-treated (25, 50, 100 mg·kg-1 ) group and donepezil group. Memory acquisition impairment model in mice was established with i. p. scopolamine (4 mg·kg-1 ) only once, and orally administered CDPS (25, 50, or 100 mg · kg-1 ) daily for 6 weeks before scopolamine injection. Experimental groups were subjected to step-down test and Morris water maze test. Western blot and RT-PCR analysis were used to examine the expression of GAP-43 , SYP and PSD-95 . Transmission electron microscope was used to observe the change of synaptic number and structures. Results CDPS (25,50,100 mg·kg-1 ) could shorten the incubation period of mice in the water maze test. Control group and CDPS-treated group swam longer in Q3 than scopolamine group. Mo-reover, CDPS (50,100 mg·kg-1 ) could significantly reduce the error times and extend the incubation period in the step-down test. The results of Western blot and RT-PCR showed that CDPS significantly improved the expression of GAP-43 at the dose of 25 ,50 mg · kg-1 and SYP at the dose of 25,50, 100 mg·kg-1 in hip-pocampus of mice. However, the biochemical assays did not reveal a significant difference in the basal hipp-ocampal levels of the PSD-95 . The ultra-thin speci-mens of hippocampus showed that the number of syn- apse was increased in CDPS-treated group. Conclu-sions Scopolamine can induce the learning and mem-ory deficits in mice to make related protein expression abnormalities in hippocampus mice, thus this causes the change of synaptic plasticity, which leads to a change in the ability of learning and memory. And CDPS can improve the expression of SYP and GAP-43 , increase number of synapses, recover synaptic plastici-ty, and improve the ability of learning and memory in mice.